Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and PK of GSK2982772 in Healthy Subjects
NCT03305419Phase 1Completed
- Sponsor
- GSK
- Start
- Oct 2017
- Primary completion
- Oct 2018
- Modality
- Orthosteric Ligands
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of GSK2982772 in autoimmune diseases (12 arms), sponsored by GSK. Primary endpoints: Number of Subjects With Adverse Events (AEs) and Serious AEs (SAEs), Number of Participants With Worst Case Clinical Chemistry Parameters by Potential Clinical Importance Criteria and 4 more. Started Oct 2017; status: completed.
02
Drugs
GSK2982772
03
Conditions
autoimmune diseases
Beyond the preview
Go deeper on NCT03305419.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03305419.